GlassScriptPhysician profile
Wendy Lucente Cleary
NPI 1629193362
$2,528.61
in general payments reported to CMS, 2019-2025
23 companies · $959 in 2025
The $959 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $102 · 2022: $92.06 · 2023: $518 · 2024: $857 · 2025: $959.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,334.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $413.72 | 2023-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $367.35 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.95 | 2021-2025 | Jardiance |
| Pfizer INC. | $291.27 | 2023-2025 | |
| Lilly USA, LLC | $250.74 | 2022-2025 | Zepbound, Mounjaro |
| Glaxosmithkline, LLC. | $120.65 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $92.21 | 2024-2025 | Evenity, Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $85.32 | 2021 | |
| Dexcom, INC. | $84.75 | 2024-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $75.70 | 2023-2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.15 | 2024-2025 | Xifaxan |
| Edwards Lifesciences Corporation | $55.29 | 2025 | |
| Antares Pharma, INC. | $46.06 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Abbvie INC. | $43.24 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $40.83 | 2024 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $32.33 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $28.07 | 2025 | Neffy |
| Optinose US, INC. | $28.02 | 2025 | |
| Astellas Pharma US INC | $28.00 | 2025 | Veozah |
| Viiv Healthcare Company | $25.92 | 2024 | Apretude |
| Almatica Pharma LLC | $20.84 | 2024 | Loreev Xr |
| Kowa Pharmaceuticals America, INC. | $20.50 | 2024 | Livalo |
| Esperion Therapeutics, INC. | $18.70 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Cleary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.